NCT06305910 2024-03-12
CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults
OX2 Therapeutics
Phase 1 Recruiting
OX2 Therapeutics
Eli Lilly and Company
Merck Sharp & Dohme LLC